endocrinology

Ertugliflozin PBS listing offers more triple therapy options in T2D

The SGLT2 inhibitor drug ertugliflozin is now listed on PBS for use as triple oral therapy in patients with Type 2 diabetes mellitus in fixed dose combination (FDC) products with sitagliptin or metformin. Marketed under the brand name Steglatro by MSD, the drug was PBS listed on 1 December 2018 for patients with uncontrolled T2DM (as ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic